RecruitingPHASE1, PHASE2NCT05295433
An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705
Studying Methylmalonic acidemia due to methylmalonyl-CoA epimerase deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- ModernaTX, Inc.
- Intervention
- mRNA-3705(drug)
- Enrollment
- 56 target
- Eligibility
- 1 years · All sexes
- Timeline
- 2022 – 2034
Study locations (12)
- UCLA Medical Center, Los Angeles, California, United States
- Lucile Packard Children's Hospital at Stanford, Palo Alto, California, United States
- Altman Clinical and Translational Research Institution, San Diego, California, United States
- Stollery Children's Hospital University of Alberta, Edmonton, Alberta, Canada
- Hospital For Sick Children, Toronto, Ontario, Canada
- Hôpital Necker - Enfants Malades APHP, Paris, France
- Erasmus MC, Rotterdam, Netherlands
- Universitair Medisch Centrum Utrecht, Utrecht, Netherlands
- Hospital Universitario Cruces, Barakaldo, Vizcaya, Spain
- Hospital Universitario 12 de Octubre, Madrid, Spain
- Birmingham Children's Hospital NHS Foundation Trust, Birmingham, United Kingdom
- Royal Manchester Childrens Hospital, Manchester, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05295433 on ClinicalTrials.gov